National Lipid Association Online |

Features

Ionis Receives FDA Approval for TRYNGOLZA (Olezarsen) for Adults with FCS

On December 19, 2024, Ionis Pharmaceuticals, Inc. received FDA approval for TRYNGOLZA (Olezarsen) as an adjunct to...

Call for NLA Board Nominations is Open!

Call for Nominations is open for the National Lipid Association Board of Directors and Chapter officers and will...

From a to B, then Back to LDL: Transatlantic Views on the Lipoproteins that Cause Plaque

The National Lipid Associations outstanding joint session with the European Atherosclerosis Society originally...

NLA Unveils New Mission to Advance Lipidology and Cardiometabolic Health

JACKSONVILLE, Fla. – (May 31, 2024) - The National Lipid Association (NLA) is proud to announce its renewed mission: “...

Arrowhead Pharmaceutials Announces the Publication of Two Back-to-back NEJM Manuscripts

Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed...

Features